Neuroprotective potential of a plant-based intervention in diabetic neuropathy: Biochemical and behavioral insights from a streptozotocin-induced rat model

Table 3 The effect of polyherbal extract treatment on lipid profile of control and experimental groups, mean ± SEM

Groups/parameters1	Total cholesterol (mg/dL)	Triglycerides (mg/dL)	High-density lipoprotein cholesterol (mg/dL)	Low-density lipoprotein cholesterol (mg/dL)	Very low-density lipoprotein cholesterol (mg/dL)
Control	125.33 ± 3.2	98.57 ± 4.3	58.62 ± 1.9	47.0 ± 2.3	19.71 ± 1.8
Diabetic	288.75 ± 4.7c (+130.39%)	187.05 ± 5.3b (+89.776%)	27.34 ± 1.6b (-53.36%)	224.0 ± 4.6c (+376.59%)	37.41 ± 1.9b (+89.80%)
Diabetic + PHE	178.44 ± 3.9e (-38.20%)	158.34 ± 5.2d (-15.35%)	42.33 ± 2.4e (+54.83%)	104.4 ± 3.8e (-53.39%)	31.67 ± 1.6d (-15.34%)
Diabetic + Met	148.42 ± 4.2f (-48.59%)	139.22 ± 4.9d (-25.57%)	48.78 ± 2.9e (+78.42%)	71.8 ± 3.2f (-67.95%)	27.84 ± 1.7d (-25.58%)
Control + PHE	130.65 ± 3.3 (+4.24%)	119.76 ± 4.4 (+21.49%)	52.65 ± 3.1 (-10.18%)	54.1 ± 3.1 (+15.11%)	23.92 ± 2.1 (+21.36%)

¹The diabetic group showed a significant increase in total cholesterol, triglycerides, low-density lipoprotein cholesterol and very low-density lipoprotein cholesterol with a significant decrease in high-density lipoprotein cholesterol compared with the control group. Polyherbal extract treatment significantly augmented these parameters in the diabetic + polyherbal extract group compared with the diabetic group. Values in parentheses indicate percentage increase (+) or decrease (-) as compared with the control or the diabetic group.

^bP < 0.01 vs control group.

^cP < 0.05 vs control group.

^dP < 0.001 vs diabetic group.

^eP < 0.01 vs diabetic group.

^fP < 0.05 vs diabetic group.

PHE: Polyherbal extract; Met: Metformin.